Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck Acquires Immune Design

Shares of Immune Design skyrocketed after Merck announced the acquisition of the Seattle-based oncology company for $300 million in cash.

Read More »

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co. shareholders for the U.S. drug maker’s $74 billion deal to buy Celgene Corp., people familiar with the matter said.

Read More »

Bayer acquires full Vitrakvi rights from Eli Lilly’s Loxo

German drugmaker Bayer acquired all rights the company does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly’s Loxo Oncology.

Read More »

J&J acquires Auris Health for $3.4 billion

Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health Inc., a company that has developed robotic endoscopic technologies for the treatment of lung cancer.

Read More »

Navitas Life Sciences Announces Acquisition of DataCeutics to Augment Global Clinical Data Science Services

Navitas Life Sciences, a TAKE Solutions Enterprise, announced that the company will acquire Life Sciences services player DataCeutics in North America.

Read More »

IFM Therapeutics Launches New Subsidiary Aimed at Parkinson’s and NASH

IFM Therapeutics launched a second subsidiary in less than a year. The Boston-based company launched IFM Due, a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases such as NASH, lupus and Parkinson’s.

Read More »

Novartis 2019 growth outlook leaves investors wanting more

Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.

Read More »

Bristol-Myers pulls U.S. application for combo lung cancer treatment

Bristol-Myers Squibb withdrew the U.S. approval application for a combo of the cancer immunotherapy drugs Opdivo and Yervoy.

Read More »

Weeks After $74 Billion Acquisition, Celgene Strikes Two Cancer Deals

Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.

Read More »

Lilly’s cancer therapy Lartruvo fails study, shares drop

Eli Lilly’s shares fell after the cancer treatment Lartruvo – approved on an accelerated basis in 2016 – failed to improve patient survival in a long-term study and will no longer be prescribed.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom